Close Menu

This article has been updated with comments from Genentech.

NEW YORK – The latest data from Genentech's MyPathway basket trial suggests that patients with rare salivary gland cancers should be genomically profiled to give them the opportunity to receive molecularly guided targeted treatment instead of more toxic chemotherapy or radiotherapy.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.